Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 10/20 | 0.51 |
| ▸ | PRKDC | P78527 | 2/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459736 | 0.90 | ATR (0.56) | ATRPRKDCPIK3CDPIK3CAPIK3CG | |
| SCHEMBL3461838 | 0.88 | ATR (0.55) | ATRPIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL3852663 | 0.87 | RAB9A (0.46) | NPC1ALDH1A1TP53PKMRAB9A | |
| SCHEMBL3462574 | 0.84 | ATR (0.68) | ATRPRKDCPIK3CDPIK3CAPIK3CG | |
| SCHEMBL3460789 | 0.81 | PLK1 (0.50) | ATRPRKDCPIK3CDPIK3CAPIK3CG | |
| SCHEMBL3460735 | 0.81 | PIK3CD (0.64) | ATRPRKDCPIK3CDPIK3CAPIK3CG | |
| SCHEMBL3461606 | 0.80 | ATR (0.55) | ATRPRKDCPIK3CDPIK3CAPIK3CG | |
| SCHEMBL3461135 | 0.78 | PIK3CD (0.47) | ATRPRKDCPIK3CDPIK3CAPIK3CG | |
| SCHEMBL3462755 | 0.76 | ATR (0.51) | ATRPRKDCPIK3CDPIK3CAPIK3CG | |
| SCHEMBL3461940 | 0.75 | PIK3CD (0.59) | ATRPRKDCPIK3CDPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | ATR 556/4885PRKDC 124/4885PIK3CD 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.